News & insights
Date: May 2022 | Client: Unitaid | Sector: Global health | Expertise: Health economics & evaluation
Evaluation of Unitaid’s COVID-19 portfolio of investments
CEPA was appointed by Unitaid to undertake a portfolio-level evaluation assessing the contribution of Unitaid’s COVID-19 response between March 2020 and October 2021, and alignment with the ACT-A partnership. The evaluation drew on evidence and examples from 27 investments, across four different pillars of work (diagnostics, therapeutics and oxygen as well as cross-cutting grants focused on advocacy).
The objective of the evaluation was twofold:
- To assess the extent to which Unitaid’s COVID-19 investments contributed to the COVID-19 response, particularly in providing catalytic support, shaping market access and country preparedness for the adoption of COVID-19 diagnostics and treatment options.
- To draw lessons learnt and forward looking recommendations for Unitaid to apply to its existing and future COVID-19 investments.
The evaluation involved undertaking a detailed desk review, key informant interviews, data analysis and country perspectives of four countries (Cameroon, India, Kenya and Senegal) where a number of grants have been implemented. CEPA also hosted three workshops to solicit feedback and presented the evaluation to the Unitaid Board.
The evaluation report is available to download from Unitaid.
To find out more, please contact our experts listed below.
